

BIOLIDICS LIMITED

(Company Registration Number: 200913076M)

RESPONSE TO SGX'S QUERY REGARDING TRADING ACTIVITY

Question 1: Are you (the issuer) aware of any information not previously announced concerning you, your subsidiaries or associated companies which, if known, might explain the trading? Such information may include events that are potentially material and price-sensitive, such as discussions and negotiations that may lead to joint ventures, mergers, acquisitions or purchase or sale of a significant asset. You may refer to paragraph 9 in Appendix 7A of the Catalist Rules for further examples.

- If yes, the information shall be announced immediately.

Company's response: The Board of Directors ("**Board**" or "**Directors**") of Biolidics Limited (the "**Company**") refers to the various announcements and press releases made by the Company relating to its rapid test kits for Novel Coronavirus 2019 (the "**COVID-19 Rapid Test Kits**") on 30 March 2020, 1 April 2020, 6 April 2020, 9 April 2020, 13 April 2020, 15 April 2020 and 20 April 2020 (the "**Public Announcements**").

Following the procurement of the relevant approvals or authorisations for its COVID-19 Rapid Test Kits as disclosed in the Public Announcements, the Company is actively developing the market for the product in Singapore, the Philippines, the European Union as well as the United States of America ("**USA**"). The Company is also pursuing regulatory authorisation for the COVID-19 Rapid Test Kits in certain other jurisdictions (the "**Regulatory Authorisations**"). With regards to the USA, the Company is in the final stages of negotiation with a potential distributor for the sale of the COVID-19 Rapid Test Kits in the USA. The Company will make the appropriate announcements as and when any definitive agreement for the distribution of its COVID-19 Rapid Test Kits has been entered into or when there are material developments in relation to the Regulatory Authorisations.

Save as set out above, the Company is not aware of any information not previously announced concerning the Company and its subsidiaries which, if known, might explain the trading.

Question 2: Are you aware of any other possible explanation for the trading? Such information may include public circulation of information by rumours or reports.

Company's response: Save for the information or developments which have been disclosed in the Public Announcements, the Company is not aware of any other explanation for the trading.

Question 3: Can you confirm your compliance with the listing rules and, in particular, Catalist Rule 703?

Company's response: The Company confirms that it is in compliance with the listing rules and, in particular, Catalist Rule 703.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
22 April 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.